-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $40

Benzinga·12/22/2025 12:40:27
Listen to the news
Piper Sandler analyst David Amsellem maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $30 to $40.